Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor–positive breast cancer
Connie Lau(University of Houston), Meghana V. Trivedi(University of Houston), Susan Abughosh(University of Houston), Erika N. Brown(Methodist Hospital), Rodrigo De La Torre(Methodist Hospital), Krista LaBorde(University of Houston), Shahad S Alfartosy(University of Houston), Bilqees Fatima(University of Houston)
Cited by 3
Related Papers
Metastasis Dormancy in Estrogen Receptor–Positive Breast Cancer
|Clinical Cancer Research|2013|273
Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize
|Cancer Research|2018|221
Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications
|Breast Care|2013|200
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancer
|Proceedings of the National Academy of Sciences|2016|185
The changing role of ER in endocrine resistance
|The Breast|2015|133